# Study to Assess an Interphase Cycle With Flotetuzumab.

> **NCT05063123** · PHASE2 · WITHDRAWN · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland**

## Conditions studied

- AML

## Interventions

- **DRUG:** Flotetuzumab

## Key facts

- **NCT ID:** NCT05063123
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2024-08
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal of MacroGenics (pharmaceutical company)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063123, "Study to Assess an Interphase Cycle With Flotetuzumab.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05063123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*